Erleada Add-on Significantly Extends Survival in Non-metastatic CRPC, SPARTAN Analysis Shows

Erleada Add-on Significantly Extends Survival in Non-metastatic CRPC, SPARTAN Analysis Shows
Adding Erleada (apalutamide) to androgen deprivation therapy (ADT) significantly extends the lives of men with non-metastatic castration-resistant prostate cancer (CRPC) by more than one year, a final analysis of the SPARTAN Phase 3 clinical trial shows. Representing a 22% reduction in the risk of death in men at high risk of developing metastasis, the findings add up to positive results across all other SPARTAN's primary, secondary, and exploratory goals. That includes a significant extension by more than two years in the time lived without metastasis — a result that granted Erleada its approval in the the U.S. and European Union for this patient population. “Treatment for patients with non-metastatic castration-resistant prostate cancer is primarily focused on delay of metastases and improvement of overall survival,” Eric Small, MD, lead SPARTAN investigator, said in a press release. “The final analysis of SPARTAN includes long-term data for each of these treatment parameters and helps to support the earlier use of apalutamide [Erleada] versus ADT alone,” added Small, who also is chief scientific officer at the Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco. Results will be presented at the American Society of Clinical Oncology (ASCO) Virtual Scientific Programme, which starts May 29, in the poster, "Final survival results from SPARTAN, a phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC)." Erleada, developed by Janssen, is a form of hormone therapy that blocks the androgen receptor, preventing male hormones, or androgens, from sending chemical signals that stimulate cancer growth. ADT, a standard prost
Subscribe or to access all post and page content.